A first-in-human phase I clinical trial in adult AML patients showed that the adoptive transfer of HLA haploidentical, IL-12, IL-15, and IL-18 pre-activated NK cells was safe and feasible with peak persistence between day 7 and day 14. This evidence concerns the gene IL15 and acute myeloid leukemia.